Summary & Overview
HCPCS S1030: Continuous Noninvasive Glucose Monitoring Device, Purchase
HCPCS Level II code S1030 designates the purchase of a continuous noninvasive glucose monitoring device. Such devices are increasingly relevant nationally as diabetes management incorporates continuous monitoring technologies to improve glucose control and reduce complications. This code covers acquisition of the monitoring device itself; physician interpretation of the device data is reported separately using CPT codes.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what S1030 represents, where the device is typically used, and which payers commonly adjudicate claims for device purchases. The publication also outlines typical billing considerations, common modifiers provided in the input, and areas where coding and reimbursement interactions occur (for example, device purchase versus professional interpretation).
The piece provides national context on clinical utility, expected sites of service, and payer coverage themes. It also identifies gaps where specific payer policies, coding crosswalks, and ICD-10 linkage are not available in the input. This summary equips revenue cycle and clinical staff to recognize the code’s purpose and to seek payer-specific guidance for coverage and billing procedures.
Billing Code Overview
HCPCS Level II code S1030 describes the purchase of a continuous noninvasive glucose monitoring device intended to capture and transmit interstitial glucose data without invasive sensors. The service type is durable medical equipment / device purchase, and the typical site of service is ambulatory or outpatient settings where the device is used by or furnished to a patient for ongoing glucose monitoring.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with type 2 diabetes mellitus on intensive insulin therapy presents for evaluation of glucose patterns after recurrent nocturnal hypoglycemia and variable daytime hyperglycemia. The clinician orders a continuous noninvasive glucose monitoring device purchase for use in outpatient management. The device is supplied to the physician for interpretation of continuous interstitial glucose data over several days; the physician reviews downloaded trend reports, identifies hypoglycemia unawareness and postprandial excursions, and documents a management plan to adjust insulin dosing. Typical workflow: device is ordered and procured by the practice (device billed as a purchase using S1030), device is applied to the patient or patient self-applies per manufacturer instructions, continuous data is captured over the monitoring period, the practice downloads and aggregates the data, and the interpreting clinician documents a review and medical decision making based on the device data. The service is usually provided in an outpatient clinic or ambulatory care setting; purchase billing occurs at the time the practice acquires the device for patient use. Payers involved in coverage determination commonly include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation component separate from device supply or technical service |